“We are enthusiastic about Courier’s proprietary cell-targeting technology because we believe it positions Valo to create a new frontier in cancer-immunotherapies,” said David Berry, Valo CEO. “This acquisition provides Valo with a unique opportunity to expand our proprietary capabilities into protein therapeutics, thereby extending our modalities and our reach while enabling us to potentially pioneer precision […]
Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications.
Oversubscribed Series B co-led by Abingworth and Tybourne Capital Management, and joined by Fidelity Management & Research Company and Intermediate Capital Group (ICG) as well as existing investors RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital.
Wugen technology licensed from Washington University in St. Louis.
While the compound needs additional verification and testing, the researchers say there is tremendous potential for this compound or others like it and could help to convert second-line drugs into first-line drugs and return others to the market. With assistance from the Washington University Office of Technology Management, they have patented the compound, and Cui has founded a startup company, VivoCor, to continue to work on the compound and others like it as potential drug candidates.
DiAntonio and Milbrandt co-founded a startup biotechnology company called Disarm Therapeutics with a focus on developing treatments for neurodegenerative diseases. Global pharmaceutical maker Eli Lilly and Company recently acquired Disarm, with the goal of speeding development of new therapies for a variety of devastating neurological conditions caused by the deterioration of axons, the vital wiring of the nervous system.
WashU’s quick start licensing program was developed five years ago, also because the tech transfer staff was spending way too much time discussing licensing terms with start-ups, she says.
“Arch Oncology’s highly differentiated approach to the development of anti-CD47 agents is a promising development in the immuno-oncology space,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology. “We look forward to continuing to support the Company as it develops and advances its robust pipeline of promising drug candidates, including a broad clinical program for AO-176.”
Innovative multidisciplinary research at Washington University led to development of ‘breakthrough’ device
Technology allows electrophysiologists to visualize cardiac anatomy in hands-free, real-time 3D
The Phase 1 human clinical trials of Hyderabad-based vaccine maker Bharat Biotech’s intranasal Covid-19 vaccine, codenamed BBV154, have commenced at some of the selected sites that include Hyderabad and Nagpur.
Join the WashU Office of Technology Management for this annual event honoring: 2020 Patent Awards New Faculty Startups — Caeli Vascular, Capella Imaging, Coordinate Medical Systems, DeepSight Technology, HSpeQ, Integro Theranostics & Percayai National Academy of Inventors Fellows & Senior Member — Randall Bateman, Richard Cote, Michael Diamond & Scott Hultgren Thursday, April 15, 20214:30 […]
Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today announced that it has entered into an exclusive license agreement with Washington University in St. Louis, one of the world’s leading research institutions, for the development of Wugen’s Memory Natural Killer (NK) Cell program.
St. Louis-based C2N Diagnostics has developed what it says is the first blood test to help diagnose Alzheimer’s disease. Now it has plans to take the technology global.
Encodia is a WashU faculty startup. The company is developing revolutionary tools for large-scale protein analysis to enable breakthrough insights into biology and the prevention, diagnosis, and treatment of disease.
Drs. Randall Bateman and David Holtzman, founders of C2N and neurology professors at Washington University School of Medicine in St. Louis, recently explained their amyloid blood test to Fox News.
Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a manufacturing giant of vaccines, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets.
With this article, we wanted to articulate the need and history of Equalize 2020, the experiences of those involved, and our thoughts on where to take this effort next.
New Faculty Startups (FY July 1, 2019 – June 30, 2020) Caeli VascularCapella ImagingCoordinate Medical SystemsDeepSight TechnologyHSpeQIntegro TheranosticsPercayai The new startups will be introduced at the annual WashU Celebration of Inventors on April 15, 2021 via Zoom.